Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Neuromodulation of Inflammation and Vascular Function in Systolic Heart Failure

NCT: NCT03945058 · TERMINATED

NCT IDNCT03945058
StatusTERMINATED
Start Date2020-02-04
Completion2021-12-16

Brief Summary

Heart failure (HF) is the leading cause of death in US. It is associated with abnormal vascular function termed endothelial dysfunction. It is also associated with increased stress on the blood vessels and high levels of inflammation. Vagus nerve stimulation can help improve inflammation, vascular function and vascular stress. The investigator has recently completed a study showing that 1 hour of noninvasive vagus stimulation can improve vascular health. However, it is unknown if 4 weeks of stimulation will be beneficial in systolic heart failure. The purpose of this study is to determine if transcutaneous vagal stimulation (TVS) will lead to improvement in the function of the inner lining of participants' arteries, memory, and in the levels of certain chemical markers of arterial function in the blood. Participants will be randomized to receive either TVS or a sham stimulation and undergo 4 weeks of stimulation. Vascular function will be assessed by several non-invasive measurements, including Flow Mediate Dilation (FMD), Pulse Wave Analysis (PWA), EndoPAT, and Laser Speckle Contrast Imaging (LSCI). Participants' memory will also be measured through electronic assessments and blood will be collected and analyzed for arterial function chemical markers.

Frequently Asked Questions

What is Neuromodulation of Inflammation and Vascular Function in Systolic Heart Failure?

Neuromodulation of Inflammation and Vascular Function in Systolic Heart Failure is a clinical trial registered under NCT03945058. Current status: TERMINATED.

What is the status of NCT03945058?

The current status of NCT03945058 (Neuromodulation of Inflammation and Vascular Function in Systolic Heart Failure) is: TERMINATED.

When did Neuromodulation of Inflammation and Vascular Function in Systolic Heart Failure start?

Neuromodulation of Inflammation and Vascular Function in Systolic Heart Failure started on 2020-02-04.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.